血清CA153、CA125和CEA联合检测在乳腺癌诊断中的应用

Objective To study the clinical singificance of serum tumor markers (CA153, CA125 and CEA) in doagnosis of breast cancer. Methods Electrochemiluminescence immunoassay (ECLIA) was used to analyze serum levels of CA153,CA125 and CEA in 55 patients with breast canc-er (breast cancer group),20 patients with benign breast lesions (benign breast lesion group) and 20 healthy controls (healthy control group). Results The levels of CA153, CA125 and CEA in breast cancer group were significantly higher than those in healthy control group (P<0.05); the levels of CEA and CA153 in breast cancer group were significantly higher than those in benign breast lesion group (P<0.05);the level of CA153 in postoperative patients was statistically lower than that in pre-operative patients (P<0.05);the levels of CEA and CA153 in breast cancer patients with stage Ⅲ and Ⅳ were significantly higher than those in healthy controls (P<0.05); the level of CA153 with stage Ⅲ and Ⅳ was higher than that in ones with stage Ⅰ and Ⅱ. The combined dection of CA153, CA125 and CEA in breast cancer patients increased the experimental sensitivity to 53.8% and specific-ity to 83.3%. Conclusion Detections of CA153,CA125 and CEA contribute to diagnosis of breast cancer. CA153 and CEA are of clinical practical value in differential diagnosis of benign and malignant breast tumor,monitoring of course of breast cancer.

Clinical application of combined detection of serum CA153, CA125 and CEA in doagnosis of breast cancer